Last $107.28 USD
Change Today -0.48 / -0.45%
Volume 439.6K
AGIO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

agios pharmaceuticals inc (AGIO) Snapshot

Open
$107.25
Previous Close
$107.76
Day High
$108.40
Day Low
$105.71
52 Week High
01/15/15 - $138.85
52 Week Low
03/3/14 - $28.81
Market Cap
4.0B
Average Volume 10 Days
739.5K
EPS TTM
$-1.59
Shares Outstanding
37.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AGIOS PHARMACEUTICALS INC (AGIO)

agios pharmaceuticals inc (AGIO) Related Bloomberg News

View More Bloomberg News

agios pharmaceuticals inc (AGIO) Related Businessweek News

No Related Businessweek News Found

agios pharmaceuticals inc (AGIO) Details

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

128 Employees
Last Reported Date: 02/24/15
Founded in 2007

agios pharmaceuticals inc (AGIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $425.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $269.1K
Chief Operating Officer
Total Annual Compensation: $350.0K
Chief Scientific Officer
Total Annual Compensation: $376.0K
Compensation as of Fiscal Year 2013.

agios pharmaceuticals inc (AGIO) Key Developments

Agios Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Agios Pharmaceuticals, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Agios Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Agios Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $14,636,000 against $6,744,000 a year ago. Loss from operations was $26,727,000 against $12,242,000 a year ago. Loss before provision for income taxes was $26,642,000 against $12,213,000 a year ago. Net loss was $26,664,000 against $12,382,000 a year ago. Net loss per share applicable to common stockholders basic and diluted was $0.76 against $0.40 a year ago. For the year, the company reported collaboration revenue of $65,358,000 against $25,548,000 a year ago. Loss from operations was $54,133,000 against $38,883,000 a year ago. Loss before provision for income taxes was $53,930,000 against $38,828,000 a year ago. Net loss was $53,504,000 against $39,407,000 a year ago. Net loss per share applicable to common stockholders basic and diluted was $1.59 against $2.83 a year ago.

Agios Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 17, 2015

Agios Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 17, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGIO:US $107.28 USD -0.48

AGIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGIO.
View Industry Companies
 

Industry Analysis

AGIO

Industry Average

Valuation AGIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.6x
Price/Book 9.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 55.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGIOS PHARMACEUTICALS INC, please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.